Mark Ragosa - 03 Jan 2024 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
03 Jan 2024
Net transactions value
-$134,040
Form type
4
Filing time
04 Jan 2024, 16:30:52 UTC
Previous filing
06 Sep 2023
Next filing
03 Apr 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Options Exercise $105,960 +12,000 +77% $8.83 27,632 03 Jan 2024 Direct F1
transaction KNSA Class A Common Share Sale $240,000 -12,000 -43% $20.00 15,632 03 Jan 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Share Option Options Exercise $0 -12,000 -100% $0.000000* 0 03 Jan 2024 Class A Common Share 12,000 $8.83 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 22, 2023.
F2 This option is fully vested and exercisable.